Waldencast Soars 27.22% on Obagi Medical's Strong Growth

On August 19, 2025, Waldencast surged 27.22% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Waldencast's recent performance has been driven by strong results from its subsidiary, Obagi Medical. The company reported double-digit growth in its core strategic channels for the first half of 2025. This growth is attributed to the successful acquisition of Novaestiq, which has doubled the brand's addressable market in the U.S. The acquisition has not only expanded Waldencast's market reach but also reinforced its position as a leader in medical-grade skincare.

Waldencast's strategic transformation initiatives have also played a crucial role in its recent success. The company's focus on driving business priorities and implementing transformation strategies has resulted in strong progress and a leading unaided brand awareness. These efforts have underscored Waldencast's dominance in the medical-grade skincare market and have positioned the company for continued growth.